#82 Strong Clinical Relevance
High-quality evidence with meaningful patient or clinical significance.
Clinicians treating athletes should understand that major sports organizations now permit cannabis use, which may influence patient disclosure patterns and create opportunities to discuss evidence-based cannabinoid therapies for pain and injury management. This policy shift reflects evolving clinical acceptance of cannabinoids for specific indications like neuropathic pain and post-concussion symptoms, conditions commonly seen in sports medicine and neurology practices. Patients may now feel more comfortable discussing cannabis use with providers, enabling better medical documentation and integration of these treatments into comprehensive pain and injury management plans.
The Women’s National Basketball Association (WNBA) has removed marijuana from its banned substances list and established guidelines permitting players to use cannabis for medical purposes, particularly cannabidiol (CBD) for pain management and neuroprotection following concussions. This policy shift reflects growing clinical recognition of cannabis efficacy for sports-related injuries and aligns with evolving medical evidence supporting cannabinoid use for acute and chronic pain conditions. The decision may influence other professional sports organizations to reconsider restrictive cannabis policies, potentially increasing athlete access to an alternative pain management strategy that could reduce opioid dependence. For clinicians treating active and former athletes, this policy change signals a shift in the competitive sports landscape and may prompt more open conversations with patients about cannabis as a legitimate therapeutic option for post-injury recovery and concussion-related symptoms. Clinicians should be prepared to discuss evidence-based cannabis use protocols, appropriate dosing, and monitoring for athletes who may now pursue this treatment option within their sport’s framework.
“What we’re seeing with professional sports organizations reconsidering cannabis policy is a recognition that cannabinoids, particularly CBD, have legitimate therapeutic applications for pain and neuroinflammation that deserve serious clinical consideration rather than blanket prohibition—and frankly, this shift in policy often precedes what the medical evidence already supports for our patients managing similar injuries.”
🏀 The WNBA’s decision to remove marijuana from its banned substances list reflects growing recognition among professional sports organizations that cannabis, particularly CBD, may have legitimate therapeutic applications for pain and injury management. However, clinicians should note that while preclinical evidence suggests CBD’s potential neuroprotective effects, robust clinical trials in athletes remain limited, and the quality, potency, and cannabinoid profiles of available products are largely unregulated. It is important to acknowledge that policy changes in professional sports can create patient expectations that may outpace the actual clinical evidence base, and individual athletes may have different injury profiles and pain management needs that warrant individualized assessment rather than reliance on policy shifts alone. Additionally, cannabis use in athletes raises questions about drug testing in other competitive contexts, potential cognitive effects, and interactions with other medications that should be part of any clinical conversation. When patients ask about cannabis for sports-related injuries or pain, clinicians should discuss the current
This topic comes up in consultations often.
Dr. Caplan offers clinical context on evolving cannabis policy and its real-world implications for patients.
Book a consultation →💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
